Zimmer Biomet Holdings (ZBH) seems to have had a fluctuating performance, underperforming compared to competitors but also outperforming despite losses on some occasions. The company has been gaining from ROSA sales growth, even amidst FX troubles. The firm's market recovery and global growth have contributed to its value stock status. The company's first quarter 2024 financial result reveals a beat on Q1 profit estimates due to robust demand for knee, hip devices, prompting the belief that it may be undervalued. International Assets Investment Management LLC has increased its holdings in ZBH. Q4 and full-year 2023 results indicate solid growth, however, investor three-year losses amount to 26%. While there are concerns about ZBH possibly using too much debt, its earnings are expected to decline for the Q1 earnings. Q3 2024 results anticipate positive earnings per share. Despite some level of underperformance, profits are projected to be upbeat in 2024 on steady medical devices demand. The company also witnessed a 5% increase in Q3 2023 net sales. ZBH has made a strong value proposition, with some suggesting that it is a top momentum stock for the long-term.
Zimmer Biomet Holdings ZBH News Analytics from Tue, 01 Aug 2023 07:00:00 GMT to Fri, 10 May 2024 08:45:57 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -6
